Source comparison
Fat Loss Peptides 2026 Update: Clinical Comparison
Semaglutide 2.4mg GLP-1 only 14.9% (STEP-1) 68% fat, 32% lean 35% FDA-approved (Wegovy) Tirzepatide 15mg GLP-1/GIP dual 20.9% (SURMOUNT-1) 78% fat, 22% lean 42% FDA-approved (Zepbound) Survodutide 6.0mg GLP-1/glucagon dual 21.2% (SYNCHRONIZE) 82% fat, 18% lean
This comparison does not assign a generated winner or score.
- Semaglutide 2.4mg
- GLP-1 only
- 14.9% (STEP-1)
- 68% fat, 32% lean
- 35%
- FDA-approved (Wegovy)
- Tirzepatide 15mg
- GLP-1/GIP dual
- 20.9% (SURMOUNT-1)
- 78% fat, 22% lean
- 42%
- FDA-approved (Zepbound)
- Survodutide 6.0mg
- GLP-1/glucagon dual
- 21.2% (SYNCHRONIZE)
- 82% fat, 18% lean
- 38%
- Phase III (not yet approved)
- Mazdutide 6.0mg
- GLP-1/GIP/glucagon triple
- 24.7% (MOMENTUM-1)
- 89% fat, 11% lean
- 52%
- Tesofensine 0.5mg
- Norepinephrine/dopamine/serotonin reuptake inhibitor
- 10.6% (Phase III)
- Data incomplete
- 18% (headache primary AE)
- Not FDA-approved; available research-grade
- The triple-agonist mechanism produces the highest absolute weight reduction but also the highest GI side effect burden. Survodutide offers a middle path: weight loss exceeding tirzepatide with side effect rates comparable to semaglutide. Lean mass preservation correlates directly with receptor breadth. Single-receptor agonists lose the most muscle, triple-agonists lose the least.